These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 35418260)

  • 1. Long-term safety and effectiveness of linagliptin by baseline body mass index in Japanese patients with type 2 diabetes: a 3-year post-marketing surveillance study.
    Yabe D; Yamamoto F; Lund SS; Okamura T; Kadowaki T
    Expert Opin Drug Saf; 2022 Oct; 21(10):1303-1313. PubMed ID: 35418260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety and effectiveness of linagliptin as add-on therapy in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance.
    Ito T; Naito Y; Shimmoto N; Ochiai K; Hayashi N; Okamura T
    Expert Opin Drug Saf; 2021 Mar; 20(3):363-372. PubMed ID: 33269625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and effectiveness of empagliflozin and linagliptin fixed-dose combination therapy in Japanese patients with type 2 diabetes: final results of a one-year post-marketing surveillance study.
    Inagaki N; Nishimoto T; Nishiya Y; Nitta D
    Expert Opin Drug Saf; 2023 Feb; 22(2):153-163. PubMed ID: 35946927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia.
    Ross SA; Caballero AE; Del Prato S; Gallwitz B; Lewis-D'Agostino D; Bailes Z; Thiemann S; Patel S; Woerle HJ; von Eynatten M
    Postgrad Med; 2016 Nov; 128(8):747-754. PubMed ID: 27684308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and effectiveness of empagliflozin according to body mass index in Japanese patients with type 2 diabetes: a subgroup analysis of a 3-year post-marketing surveillance study.
    Kaku K; Yamamoto K; Fukushima Y; Mizuno S; Nitta D
    Expert Opin Drug Saf; 2022 Nov; 21(11):1411-1422. PubMed ID: 35379060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and effectiveness of linagliptin in Korean patients with type 2 diabetes: A postmarketing surveillance study.
    Bae J; Song KH; Park JS; Lee JH; Jeong IK; Kim HJ; Lim YH; Cho JH; Choi SH; Chung YS; Kang ES
    Diabetes Obes Metab; 2021 May; 23(5):1208-1212. PubMed ID: 33464714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Safety and Effectiveness of Linagliptin in Japanese Patients with Type 2 Diabetes Mellitus: A 3-Year Post-Marketing Surveillance Study.
    Yamamoto F; Unno Y; Okamura T; Ikeda R; Ochiai K; Hayashi N
    Diabetes Ther; 2020 Jan; 11(1):107-117. PubMed ID: 31713160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Durable Safety and Effectiveness of Lixisenatide in Japanese People with Type 2 Diabetes: The Post-Marketing Surveillance PRANDIAL Study.
    Terauchi Y; Usami M; Inoue T
    Adv Ther; 2022 Jun; 39(6):2873-2888. PubMed ID: 35449321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Safety and Effectiveness of Linagliptin in Japanese Patients with Type 2 Diabetes and Renal Dysfunction: a Post-Marketing Surveillance Study.
    Yamamoto F; Ikeda R; Ochiai K; Hirase T; Hayashi N; Okamura T
    Diabetes Ther; 2020 Feb; 11(2):523-533. PubMed ID: 31933070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Safety and Effectiveness of Canagliflozin Treatment for Type 2 Diabetes Mellitus in Japan: SAPPHIRE, a Long-Term, Large-Scale Post-Marketing Surveillance.
    Inagaki N; Nangaku M; Sakata Y; Sasaki K; Mori-Anai K; Iwasaki T; Hamada K
    Adv Ther; 2022 Jan; 39(1):674-691. PubMed ID: 34853985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of linagliptin according to patient baseline characteristics: A pooled analysis of three phase 3 trials.
    Del Prato S; Patel S; Crowe S; von Eynatten M
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):886-92. PubMed ID: 27484756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preferential prescribing of linagliptin in type 2 diabetes patients in an expanded post-marketing surveillance study in Japan.
    Fazeli Farsani S; Taniguchi A; Ikeda R; Brodovicz KG; Bartels DB
    J Diabetes Investig; 2019 Sep; 10(5):1246-1253. PubMed ID: 30667173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Efficacy and Safety of Linagliptin in a Japanese Population with Type 2 Diabetes Aged ≥ 60 Years Treated with Basal Insulin: A Randomised Trial.
    Araki E; Unno Y; Tanaka Y; Sakamoto W; Miyamoto Y
    Adv Ther; 2019 Oct; 36(10):2697-2711. PubMed ID: 31482511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Safety and Efficacy of Sitagliptin for Type 2 Diabetes Mellitus in Japan: Results of a Multicentre, Open-Label, Observational Post-Marketing Surveillance Study.
    Yoshikawa K; Tsuchiya A; Kido T; Ota T; Ikeda K; Iwakura M; Maeda Y; Maekawa S
    Adv Ther; 2020 May; 37(5):2442-2459. PubMed ID: 32306246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA
    Rosenstock J; Perkovic V; Alexander JH; Cooper ME; Marx N; Pencina MJ; Toto RD; Wanner C; Zinman B; Baanstra D; Pfarr E; Mattheus M; Broedl UC; Woerle HJ; George JT; von Eynatten M; McGuire DK;
    Cardiovasc Diabetol; 2018 Mar; 17(1):39. PubMed ID: 29540217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes.
    Jax T; Stirban A; Terjung A; Esmaeili H; Berk A; Thiemann S; Chilton R; von Eynatten M; Marx N
    Cardiovasc Diabetol; 2017 Jan; 16(1):13. PubMed ID: 28109295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Linagliptin in 2681 Asian Patients Stratified by Age, Obesity, and Renal Function: A Pooled Analysis of Randomized Clinical Trials.
    Ning G; Bandgar T; Hehnke U; Lee J; Chan JCN
    Adv Ther; 2017 Sep; 34(9):2150-2162. PubMed ID: 28819835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular safety and effectiveness of vildagliptin in patients with type 2 diabetes mellitus: a 3-year, large-scale post-marketing surveillance in Japan.
    Ishida Y; Murayama H; Shinfuku Y; Taniguchi T; Sasajima T; Oyama N
    Expert Opin Drug Saf; 2020 May; 19(5):625-631. PubMed ID: 32228183
    [No Abstract]   [Full Text] [Related]  

  • 19. Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan.
    Kadowaki T; Inagaki N; Watada H; Sasaki K; Mori-Anai K; Iwasaki T; Teranishi T
    Adv Ther; 2022 Apr; 39(4):1642-1658. PubMed ID: 35138572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of linagliptin to improve glucose control in older people with type 2 diabetes on stable insulin therapy: A randomized trial.
    Ledesma G; Umpierrez GE; Morley JE; Lewis-D'Agostino D; Keller A; Meinicke T; van der Walt S; von Eynatten M
    Diabetes Obes Metab; 2019 Nov; 21(11):2465-2473. PubMed ID: 31297968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.